BioCentury | May 25, 2009
Clinical News

Nestorone/estradiol: Preliminary Phase II data

...there have been no incidences of skin irritation. Antares Pharma Inc. (NYSE-A:AIS), Ewing, N.J. Product: Nestorone/estradiol...
...the physiological early follicular phase level as assessed by ultrasound and serum estradiol, correlation between nestorone...
BioCentury | Dec 8, 2008
Clinical News

Nestorone/Estradiol: Phase II started

...a 2006 deal (see BioCentury, July 31, 2006). Antares Pharma Inc. (AMEX:AIS), Ewing, N.J. Product: Nestorone/Estradiol...
...the physiological early follicular phase level as assessed by ultrasound and serum estradiol, correlation between nestorone...
BioCentury | Jun 4, 2007
Clinical News

Nestorone/Estradiol: Phase I started

...women. The first portion of the trial will evaluate a pair of single doses of nestorone...
...is being developed with the non-profit Population Council. Antares Pharma Inc. (AIS), Ewing, N.J. Product: Nestorone/Estradiol...
...NA Description: Advanced transdermal deliver (ATD) gel contraceptive Indication: Prevent pregnancy Endpoint: Pharmacokinetics and determine nestorone...
BioCentury | Jul 31, 2006
Company News

Antares, Population Council Inc. deal

...The parties will jointly develop transdermal contraceptives using the council's IP covering Nestorone, a fourth-generation synthetic...
BioCentury | Feb 27, 2006
Company News

Acrux, Population Council Inc. deal

...Population Council granted ACR a worldwide license to IP covering the contraceptive Nestorone delivered with ACR's...
BioCentury | Apr 24, 2000
Company News

Orion Pharma, Population Council deal

...The council will grant Orion exclusive worldwide rights to develop, commercialize and sublicense Nestorone synthetic progestin...
...for hormone replacement therapy. Orion is conducting Phase II trials of a gel preparation of Nestorone...
...estrogen. The council, an international non-profit organization, holds patents covering transdermal use and compositions containing Nestorone...
BioCentury | Dec 7, 1998
Strategy

Monetizing Sano

...enter Phase III trials next year. Earlier pipeline products include a patch containing the progestin Nestorone...
BioCentury | Jul 14, 1997
Company News

Sano, The Population Council Inc. deal

...SANO received exclusive North American rights to use the Council’s Nestorone synthetic progestin in transdermal patches...
...U.S. marketing approval for Nestorone. The company has filed an IND for a patch combining Nestorone...
Items per page:
1 - 8 of 8